ATTN: As of June 9, our Harbour View office in Suffolk has relocated to 3910 Bridge Road, Ste. 400.  

2025 UPDATES: Please bring all new insurance cards to your next appointment and verify your address and phone number when you check in at the front desk. 

Clinical Research & Trials

USO 23251

A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant versus Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH non-amplified) Advanced Breast Cancer (EvoPAR-Breast01)(D9722C00001)

 

Disease Types: Breast Cancer Research

Eligibility Requirements:

Adult females, pre/peri-menopausal and/or post-menopausal, and adult males

Histologically or cytologically documented diagnosis of HR-positive, HER2-negative breast cancer

Advanced breast cancer with either locally advanced disease not amenable to curative treatment or metastatic disease

ECOG performance status of 0 or 1 with no deterioration over the previous 2 weeks

FFPE tumour tissue from each participant

Documented germline tumour loss of function mutation in BRCA1, BRCA2, or PALB2

Adequate organ and marrow function

For more information on this trial CLICK HERE .

Available at: